Psychopharmacology

Latest News

Tasty Cat/AdobeStock
Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings

February 14th 2025

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

LFK/AdobeStock
Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment

February 13th 2025

Berit Kessler/AdobeStock
Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis

February 13th 2025

Yuparet/AdobeStock
SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms

February 12th 2025

Ronstik/AdobeStock
The Week in Review: February 5-7

February 7th 2025

Video Interviews
Podcasts
Latest CME Events & Activities

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

More News

© 2025 MJH Life Sciences

All rights reserved.